Stocks News

LAST PRICE
480.7300
TODAY'S CHANGE (%)
Trending Up1.7000 (0.3549%)

Bid / Lots
475.8000/ 2
Ask / Lots
483.0000/ 1
Open / Previous Close
477.7300 / 479.0300
Day Range
Low 477.7300
High 483.5300
52 Week Range
Low 335.8200
High 486.4250
Volume
641,768
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials, from 5:13AM ET on Friday Jun 14, 2024 by MT Newswires
  5:13AM ET on Friday Jun 14, 2024 by MT Newswires
  Companies Mentioned: VRTX
  05:13 AM EDT, 06/14/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) said Friday its Casgevy gene-editing therapy demonstrated clinical benefits in trials in sickle cell disease and transfusion-dependent beta thalassemia. In sickle cell disease,...
- Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress, from 3:03AM ET on Friday Jun 14, 2024 by Business Wire
  3:03AM ET on Friday Jun 14, 2024 by Business Wire
  Companies Mentioned: VRTX
  --- Data from these trials, with the longest follow-up of more than five years, demonstrate transformative, consistent and durable benefit of CASGEVY(TM) -
  --- Safety profile consistent with busulfan conditioning and autologous hematopoietic stem cell transplant -
- Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress, from 3:03AM ET on Friday Jun 14, 2024 by Dow Jones
  3:03AM ET on Friday Jun 14, 2024 by Dow Jones
  Companies Mentioned: VRTX
  
  mediainfo@vrtx.com
  
  or
  
  International: +44 20 3204 5275
  
  or
  
  U.S.: 617-341-6992
Jun 13, 2024
- Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing, from 4:18PM ET on Thursday Jun 13, 2024 by MT Newswires
  4:18PM ET on Thursday Jun 13, 2024 by MT Newswires
  Companies Mentioned: VRTX
  04:18 PM EDT, 06/13/2024 (MT Newswires) -- Carmen Bozic, Executive Vice President and Chief Medical Officer, on June 12, 2024, sold 2,280 shares in Vertex Pharmaceuticals (VRTX) for $1,089,840. Following the Form 4 filing with the SEC, Bozic has con...
- Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing, from 4:11PM ET on Thursday Jun 13, 2024 by MT Newswires
  4:11PM ET on Thursday Jun 13, 2024 by MT Newswires
  Companies Mentioned: VRTX
  04:11 PM EDT, 06/13/2024 (MT Newswires) -- Edward Morrow Atkinson III, Executive Vice President, Chief Technical Operations Officer, on June 11, 2024, sold 7,288 shares in Vertex Pharmaceuticals (VRTX) for $3,483,664. Following the Form 4 filing wit...

Today
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA, from 5 hours ago by PR Newswire
  5 hours ago by PR Newswire
  Companies Mentioned: MRNA
Yesterday
- Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea, from 3:43PM ET on Friday Jun 14, 2024 by MT Newswires
  3:43PM ET on Friday Jun 14, 2024 by MT Newswires
  Companies Mentioned: REGN
- Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:01AM ET on Friday Jun 14, 2024 by Accesswire
  11:01AM ET on Friday Jun 14, 2024 by Accesswire
  Companies Mentioned: MRNA
Jun 13, 2024
- Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing, from 4:08PM ET on Thursday Jun 13, 2024 by MT Newswires
  4:08PM ET on Thursday Jun 13, 2024 by MT Newswires
  Companies Mentioned: REGN
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA, from 3:38PM ET on Thursday Jun 13, 2024 by GlobeNewswire
  3:38PM ET on Thursday Jun 13, 2024 by GlobeNewswire
  Companies Mentioned: MRNA
- Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:01AM ET on Thursday Jun 13, 2024 by Accesswire
  11:01AM ET on Thursday Jun 13, 2024 by Accesswire
  Companies Mentioned: MRNA
- Moderna Says its Phase 3 Trial of mRNA-1283 Meets Primary Vaccine Efficacy Endpoint Against COVID-19, from 7:47AM ET on Thursday Jun 13, 2024 by MT Newswires
  7:47AM ET on Thursday Jun 13, 2024 by MT Newswires
  Companies Mentioned: MRNA
- Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company's Next Generation COVID-19 Vaccine, from 7:01AM ET on Thursday Jun 13, 2024 by Accesswire
  7:01AM ET on Thursday Jun 13, 2024 by Accesswire
  Companies Mentioned: MRNA
Jun 12, 2024
- Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says, from 3:37PM ET on Wednesday Jun 12, 2024 by MT Newswires
  3:37PM ET on Wednesday Jun 12, 2024 by MT Newswires
  Companies Mentioned: GSK, PFE, MRNA
- Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:01AM ET on Wednesday Jun 12, 2024 by Accesswire
  11:01AM ET on Wednesday Jun 12, 2024 by Accesswire
  Companies Mentioned: MRNA

Vertex Pharmaceuticals Inc
NASDAQ:VRTXUnited States

Search Criteria

Yesterday

Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials, from 5:13AM ET on Friday Jun 14, 2024 by MT Newswires

Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress, from 3:03AM ET on Friday Jun 14, 2024 by Business Wire

Vertex Presents Positive Long-Term Data On CASGEVY(TM) (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress, from 3:03AM ET on Friday Jun 14, 2024 by Dow Jones

Jun 13, 2024

Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing, from 4:18PM ET on Thursday Jun 13, 2024 by MT Newswires

Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing, from 4:11PM ET on Thursday Jun 13, 2024 by MT Newswires

Peers Headlines

Today

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA, from 5 hours ago by PR Newswire

Yesterday

Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea, from 3:43PM ET on Friday Jun 14, 2024 by MT Newswires

Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:01AM ET on Friday Jun 14, 2024 by Accesswire

Jun 13, 2024

Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing, from 4:08PM ET on Thursday Jun 13, 2024 by MT Newswires

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA, from 3:38PM ET on Thursday Jun 13, 2024 by GlobeNewswire

Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:01AM ET on Thursday Jun 13, 2024 by Accesswire

Moderna Says its Phase 3 Trial of mRNA-1283 Meets Primary Vaccine Efficacy Endpoint Against COVID-19, from 7:47AM ET on Thursday Jun 13, 2024 by MT Newswires

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company's Next Generation COVID-19 Vaccine, from 7:01AM ET on Thursday Jun 13, 2024 by Accesswire

Jun 12, 2024

Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says, from 3:37PM ET on Wednesday Jun 12, 2024 by MT Newswires

Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 11:01AM ET on Wednesday Jun 12, 2024 by Accesswire